Table 1.
Baseline characteristics of CARE-MS I patients with sNfL samples in this analysis.
| Parameter | Overall CARE-MS I population | HAD subgroup | ||
|---|---|---|---|---|
| Alemtuzumab (n = 354) | SC IFNB-1a (n = 159) | Alemtuzumab (n = 102) | SC IFNB-1a (n = 53) | |
| Age, years | 32.9 (8.0) | 33.0 (8.3) | 32.3 (8.0) | 29.7 (7.3) |
| Female, n (%) | 232 (65.5) | 108 (67.9) | 68 (66.7) | 36 (67.9) |
| White, n (%) | 332 (93.8) | 154 (96.9) | 93 (91.2) | 51 (96.2) |
| EDSS score | 2.0 (0.8) | 2.0 (0.8) | 2.0 (0.8) | 2.1 (0.9) |
| Years since initial relapse | 2.1 (1.4) | 2.0 (1.4) | 1.7 (1.4) | 2.0 (1.5) |
| No. of relapses in prior 1 year | 1.8 (0.8) | 1.8 (0.8) | 2.3 (0.6) | 2.3 (0.6) |
| No. of relapses in prior 2 years | 2.5 (0.8) | 2.4 (0.8) | 2.8 (0.9) | 2.7 (0.9) |
| Patients with Gd-enhancing lesions, n (%) | 162 (46.4) a | 77 (49.4) b | 102 (100) | 53 (100) |
| Gd-enhancing lesion count | 2.3 (5.2) a | 2.1 (4.6) b | 5.5 (7.2) | 4.6 (5.2) |
| T2 hyperintense lesion volume, cm3 | 7.4 (9.0) a | 7.1 (10.0) c | 9.9 (10.3) | 11.4 (13.6) |
| T1 hypointense lesion volume, cm3 | 1.2 (2.1) a | 1.2 (2.4) c | 1.5 (2.1) | 2.3 (3.7) |
| Brain parenchymal fraction | 0.82 (0.02) a | 0.82 (0.02) d | 0.82 (0.02) | 0.82 (0.02) |
EDSS: Expanded Disability Status Scale; Gd: gadolinium; HAD: highly active disease; SC IFNB-1a: subcutaneous interferon beta-1a; SD, standard deviation; sNfL: serum neurofilament light chain.
All values are mean (SD) unless specified otherwise.
a
n = 349.
b
n = 156.
c
n = 157.
d
n = 158.